Incyte Reports Jakafi Data Continues to Show Improved Overall Survival for Patients with Myelofibrosis at ASH

By: Benzinga
Incyte Corporation (Nasdaq: INCY ) announced today that more than 35 analyses from clinical studies of Jakafi® (ruxolitinib) were presented at the 2013 American Society of Hematology (ASH) Annual
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.